APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-07-29

Price

$134.20

+0.02%

This is the 2026-07-29 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score5.2Watchlist

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

APGE's price action is entirely dictated by AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The stock's ultra-low annualized volatility (2.4%) and steady technical signals (SURGE, STEADY_CLIMB) reflect classic merger arbitrage behavior as shares consolidate just below the buyout price at $134.20. Despite the broader market's CAUTION regime driven by geopolitical tensions, APGE is insulated due to the cash nature of the deal. Furthermore, unfazed credit markets (OAS at 0.81%) ensure AbbVie's financing remains secure, keeping the arbitrage spread extremely tight.

Fired Signals

SURGEALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: APGE is a pure merger arbitrage play, offering a tight but highly probable spread to the $135.11 cash acquisition price by AbbVie [1.2.9].
Key Risk: Regulatory pushback regarding biotech/immunology consolidation could delay or jeopardize the Q3 2026 closing timeline.
What to Watch: Monitor the $132.77 support level, as any break below would signal institutional doubts about the deal's successful completion.

← Back to 2026-07-29 View Full APGE History →Yahoo Finance &nearr;